PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.98%
Negative revenue growth while JHX stands at 4.18%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-70.36%
Negative gross profit growth while JHX is at 3.47%. Joel Greenblatt would examine cost competitiveness or demand decline.
-93.49%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-93.49%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-0.98%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.04%
Share reduction more than 1.5x JHX's 0.09%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-0.02%
Reduced diluted shares while JHX is at 0.24%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
304.81%
10Y revenue/share CAGR above 1.5x JHX's 9.07%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
66.22%
5Y revenue/share CAGR above 1.5x JHX's 9.07%. David Dodd would look for consistent product or market expansions fueling outperformance.
39.44%
3Y revenue/share CAGR above 1.5x JHX's 9.07%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.47%
Net income/share CAGR 1.25-1.5x JHX's 199.96%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
10.49%
Below 50% of JHX's 199.96%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
69.39%
Below 50% of JHX's 199.96%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
123.77%
5Y equity/share CAGR above 1.5x JHX's 31.09%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
26.51%
3Y equity/share CAGR at 75-90% of JHX's 31.09%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.